Among the cherished goals of AMANET is to develop sustainable human and infrastructure capacity for African owned and led institutions to undertake malaria vaccine trials that are appropriate for Africans living in malaria-endemic areas.
The GMZ2:[REF] The third vaccine in the portfolio was recently initiated in phase Ib adult study in Gabon.